Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 3:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 428 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: i-CAN Clear all
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Physical Activity Modifies Exercise Responsiveness

NCT07792967
View directory record Official record
Conditions
Multimorbidity
Interventions
SLIMM - Sit less, interact, move more, PB125
Behavioral · Dietary Supplement
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
60 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2031
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 7, 2026, 3:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Clinical Performance and Reproducibility of the Accelerate PhenoTest™ Blood Culture (BC) Kit With New Antibiotic Wave I Updates

NCT04295915
View directory record Official record
Conditions
Bacteremia
Interventions
Specimens that meet inclusion criteria
Device
Lead sponsor
Accelerate Diagnostics, Inc.
Industry
Eligibility
Not listed
Enrollment
731 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
3
States / cities
Tucson, Arizona • Hershey, Pennsylvania • Lewisville, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Sep 7, 2026, 3:42 PM EDT
Recruiting Phase 1Phase 2 Interventional

Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists

NCT05463133
View directory record Official record
Conditions
Chronic Granulomatous Disease
Interventions
Sirolimus, Cyclophosphamide, Alemtuzumab, Busulfan, Pheripheral blood stem cells, Emapalumab-Izsg, Tociluzumab, Total Body Irradiation
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 7, 2026, 3:42 PM EDT
Not yet recruiting Phase 2 Interventional

Intestinal & Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)

NCT06084780
View directory record Official record
Conditions
Secondary Malignant Neoplasm of Retroperitoneum, Secondary Malignant Neoplasm of Peritoneum, Pseudomyxoma Peritonei
Interventions
Intestinal, Multivisceral or Modified Multivisceral Transplantation, Alemtuzumab, Tacrolimus, Sirolimus
Procedure · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 7, 2026, 3:42 PM EDT
Completed Phase 1 Interventional

Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab)

NCT00968240
View directory record Official record
Conditions
Glioblastoma Multiforme, Anaplastic Astrocytoma
Interventions
Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2015 · Synced Sep 7, 2026, 3:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis

NCT00594932
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Arthritis
Interventions
mycophenolate mofetil, placebo
Drug · Other
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
14 Years to 70 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Sep 7, 2026, 3:42 PM EDT
Recruiting Phase 1 Interventional

Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors

NCT05270213
View directory record Official record
Conditions
Advanced Cancer
Interventions
RBS2418, Pembrolizumab, Other approved anti-cancer therapy
Drug
Lead sponsor
Riboscience, LLC.
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
14
States / cities
Scottsdale, Arizona • Tucson, Arizona • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 7, 2026, 3:42 PM EDT
Completed Phase 1 Interventional

Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)

NCT02973113
View directory record Official record
Conditions
NonHodgkin Lymphoma, Lymphoproliferative Disorders, EBV Related Lymphoma, EBV-Related PTLD, Hodgkin Lymphoma, EBV Related Non-Hodgkin's Lymphoma, EBV Related Hodgkin's Lymphoma
Interventions
EBVST Cells, Nivolumab
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Not listed
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Sep 7, 2026, 3:42 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Adaptation and Initial Evaluation of Transdiagnostic CBT for Anxious and Depressed Smokers

NCT03920137
View directory record Official record
Conditions
Smoking Cessation
Interventions
UP-ST Therapy, Standard Therapy, Nicotine Patch
Behavioral · Device
Lead sponsor
University of Houston
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Sep 7, 2026, 3:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Boricua Youth Study COVID-19 Coping Intervention Study

NCT05444881
View directory record Official record
Conditions
Psychological Stress, Depression, Anxiety
Interventions
Mindfulness-based Intervention (Headspace TM)
Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 7, 2026, 3:42 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Effect of (TaVNS) on Anxiety and Brain Function in Distressed Health Care Workers

NCT05132881
View directory record Official record
Conditions
Anxiety, Distress, Emotional, Effects of Vibration, Healthy
Interventions
Neuvana 2.0 Transcutaneous Auricular Vagal Nerve Stimulation (TaVNS), Waitlist Control, Healthy Controls: Substudy Group III, Distressed Workers: Subgroup II
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
21 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Sep 7, 2026, 3:42 PM EDT
Recruiting Phase 1 Interventional

Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor

NCT07171203
View directory record Official record
Conditions
Gastrointestinal Stromal Tumors
Interventions
Imatinib, Fampridine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 7, 2026, 3:42 PM EDT
Completed Phase 2 Interventional Results available

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

NCT00787761
View directory record Official record
Conditions
Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
Biological · Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
Up to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2012 · Synced Sep 7, 2026, 3:42 PM EDT
Terminated Phase 1 Interventional

A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors

NCT01871311
View directory record Official record
Conditions
Colorectal Cancer, Head and Neck Cancer
Interventions
Nilotinib + Cetuximab
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Sep 7, 2026, 3:42 PM EDT
Terminated Phase 1 Interventional

Carboplatin and Etoposide Plus LBH589 for Small Cell Lung Cancer

NCT00958022
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
LBH589 and carboplatin with etoposide
Drug
Lead sponsor
Ahmad Tarhini
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2017 · Synced Sep 7, 2026, 3:42 PM EDT
Completed Not applicable Interventional Results available

Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction

NCT01208974
View directory record Official record
Conditions
Breast Cancer, Ductal Carcinoma
Interventions
Nipple-Sparing Mastectomy, Breast Reconstruction, Axillary Surgery, Prophylactic Nipple-Areolar Complex RT
Procedure · Radiation
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 7, 2026, 3:42 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Pilot Study of Pancreatic Cancer Screening

NCT05058846
View directory record Official record
Conditions
Pancreatic Carcinoma
Interventions
Biospecimen Collection, Magnetic Resonance Cholangiopancreatography, Magnetic Resonance Imaging, Endoscopic ultrasound, Questionnaires
Procedure · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2032
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 7, 2026, 3:42 PM EDT
Recruiting Phase 4 Interventional

Safety and Efficacy of ARNI After LVAD ImplanT (SEAL-IT) Study

NCT04191681
View directory record Official record
Conditions
Stage D Heart Failure
Interventions
Sacubitril-Valsartan, Usual care (standard-of-care) arm
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 6, 2021 · Synced Sep 7, 2026, 3:42 PM EDT
Completed Phase 1 Interventional

Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL

NCT01333046
View directory record Official record
Conditions
Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Disease
Interventions
Antigen-Escalation Stage, Dose-Escalation Stage, azacytidine and multiTAA T cells Stage, Pediatric multiTAA T cells Stage
Biological
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 7, 2026, 3:42 PM EDT
Completed Phase 3 Interventional Results available

A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)

NCT02549092
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Optimized Medical Treatment, Levodopa-Carbidopa Intestinal Gel, Nasojejunal (NJ) tube, Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube
Drug · Device
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
8
States / cities
Fountain Valley, California • Boca Raton, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2023 · Synced Sep 7, 2026, 3:42 PM EDT
Completed Phase 1 Interventional

Nilotinib With Radiation for High Risk Chordoma

NCT01407198
View directory record Official record
Conditions
Chordoma
Interventions
Nilotinib, Radiation therapy
Drug · Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 7, 2026, 3:42 PM EDT
Completed Phase 1 Interventional Results available

Study of Proton Therapy in Adjuvant Pancreatic Cancer

NCT03885284
View directory record Official record
Conditions
Resected Pancreatic Adenocarcinoma
Interventions
mFOLFIRINOX, Proton beam radiation
Drug · Radiation
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 23, 2024 · Synced Sep 7, 2026, 3:42 PM EDT
Completed Phase 2 Interventional

Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by Surgery

NCT00769470
View directory record Official record
Conditions
Breast Cancer
Interventions
trastuzumab, carboplatin, docetaxel, lapatinib ditosylate
Biological · Drug
Lead sponsor
Translational Oncology Research International
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
15
States / cities
Alhambra, California • Bakersfield, California • Fullerton, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Sep 7, 2026, 3:42 PM EDT
Terminated Phase 2 Interventional Results available

Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19

NCT04365985
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome, Severe Acute Respiratory Syndrome (SARS), Coronavirus Infections
Interventions
Naltrexone, Ketamine, Placebo
Drug · Other
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Sep 7, 2026, 3:42 PM EDT